Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New research platform aims to unlock secrets of brain metastases

NCT ID NCT04109131

Knowledge-focused Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with solid tumors that have spread to the brain. Researchers want to collect medical information and samples (like blood and spinal fluid) to better understand why and how brain metastases happen. The goal is to find new ways to treat or prevent them in the future. About 600 participants will join this observational research program.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2020

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years old 2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 3. Female or Male 4. Eligible for part A: Subjects (from cohorts 1 to 5) with newly diagnosed or up to 24 months from diagnosis of non-CNS metastases. Enrolment of exceptional cases surpassing 24 months from diagnosis will be allowed for up to 20% of subjects enrolled with HER2+ BC (cohort 2) and NSCLC harbouring driver mutations (cohort 3). Eligible for part B: Subjects (from cohorts 1 to 7) presenting with a first CNS event and not yet enrolled in the program Seven cohorts of subjects are defined in this prospective multicenter study: * Cohort 1: Triple negative breast cancer (TNBC) * Cohort 2: HER 2 positive breast cancer (HER2+ BC) * Cohort 3: Non-small cell lung cancer (NSCLC) * Cohort 4: Small cell lung cancer (SCLC) * Cohort 5: Melanoma * Cohort 6: Other solid tumours (apart from the above mentioned subtypes * Cohort 7: Radiologically or cytologically confirmed leptomeningeal carcinomatosis 5. Availability of either primary and/or non-CNS metastatic archival tumour tissue is mandatory for inclusion. 6. Willingness to undergo lumbar puncture at diagnosis of CNS metastases unless medical contra-indications 7. Predicted life expectancy \> 3 months. 8. Women of childbearing potential must have a negative urine pregnancy test done within 28 days prior to enrolment 9. Effective contraception is in place for women of childbearing potential 10. Completion of all necessary screening procedures within 28 days prior to enrolment. 11. Signed Informed Consent form (ICF) obtained prior to any study related procedure. Inclusion criterion applicable to FRANCE only 12. Affiliated to the French Social Security System Exclusion Criteria: 1. Pregnant and/or lactating women. 2. Previous or current malignancies of other histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin. 3. Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study. Exclusion criterion applicable to FRANCE only 4. Vulnerable persons according to the article L.1121-6 of the Public Health Code, adults who are the subject of a measure of legal protection or unable to express their consent according to article L.1121-8 of the Public Health Code.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CNS metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma melanoma neoplastic meningitis non-small cell lung carcinoma small cell lung carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CNS metastases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Ambroise Paré

    RECRUITING

    Mons, 7000, Belgium

  • CHU UCL Namur - Site de Sainte-Elisabeth

    RECRUITING

    Namur, 5000, Belgium

  • Centre Henri Becquerel

    RECRUITING

    Rouen, 76038, France

  • Centre Hospitalier de Luxembourg

    RECRUITING

    Luxembourg, 1445, Luxembourg

  • Centre Oscar Lambret

    RECRUITING

    Lille, 59020, France

  • Cliniques Universitaires St Luc

    RECRUITING

    Brussels, 1200, Belgium

  • Grand Hôpital de Charleroi

    RECRUITING

    Charleroi, 6000, Belgium

  • Hopitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, 67200, France

  • Hôpital Erasme

    RECRUITING

    Brussels, 1070, Belgium

  • Institut Curie

    RECRUITING

    Paris, 75248, France

  • Institut Jules Bordet

    RECRUITING

    Anderlecht, 1070, Belgium

  • Institut Paoli-Calmettes

    RECRUITING

    Marseille, 13273, France

  • Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Hopital Tenon

    RECRUITING

    Paris, 75020, France

  • Institut Universitaire du Cancer - Oncopole

    RECRUITING

    Toulouse, 31059, France

  • UZ Brussel

    RECRUITING

    Jette, 1090, Belgium

  • UZ Leuven

    RECRUITING

    Leuven, 3000, Belgium

  • Universitair Ziekenhuis Gent

    RECRUITING

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.